Research programme: chemokine antagonists - ICOS

Drug Profile

Research programme: chemokine antagonists - ICOS

Alternative Names: Chemokine antagonists research programme - ICOS

Latest Information Update: 26 Mar 2009

Price : $50

At a glance

  • Originator ICOS Corporation
  • Class Chemokines
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly
  • 28 Jun 2004 This programme is still in active development
  • 02 Aug 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top